GlassScriptPhysician profile
Stefan D Monev
NPI 1437125911
$2,872.32
in general payments reported to CMS, 2019-2025
23 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,115 · 2020: $454 · 2021: $14.01 · 2023: $18.48 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218 · Education: $71.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.52 |
| Education | $71.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $718.83 | 2019-2025 | Otezla, Tavneos |
| Abbvie INC. | $303.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $279.02 | 2019-2025 | |
| Pfizer INC. | $273.13 | 2019-2025 | |
| Genentech USA, INC. | $197.15 | 2019-2020 | |
| Ucb, INC. | $180.08 | 2019-2025 | Bimzelx |
| Celgene Corporation | $168.17 | 2019 | |
| Lilly USA, LLC | $151.04 | 2019-2020 | |
| Janssen Biotech, INC. | $106.26 | 2019-2020 | |
| Horizon Therapeutics Plc | $77.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.82 | 2019-2020 | |
| Radius Health, INC. | $69.46 | 2019-2025 | Tymlos |
| Genentech, INC. | $53.45 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $51.38 | 2019 | |
| Merck Sharp & Dohme LLC | $34.67 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $30.59 | 2025 | Lupkynis |
| Pacira Therapeutics, INC. | $20.57 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.43 | 2019 | |
| Antares Pharma, INC. | $15.69 | 2020 | |
| Gilead Sciences, INC. | $15.44 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.66 | 2019 | |
| Medexus Pharma, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Monev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.